3510 related articles for article (PubMed ID: 26541606)
1. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
[TBL] [Abstract][Full Text] [Related]
2. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota.
Dong M; Meng Z; Kuerban K; Qi F; Liu J; Wei Y; Wang Q; Jiang S; Feng M; Ye L
Cell Death Dis; 2018 Oct; 9(10):1039. PubMed ID: 30305604
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Not Working? Check Your Microbiota.
West NR; Powrie F
Cancer Cell; 2015 Dec; 28(6):687-689. PubMed ID: 26678336
[TBL] [Abstract][Full Text] [Related]
5. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?
Snyder A; Pamer E; Wolchok J
Science; 2015 Nov; 350(6264):1031-2. PubMed ID: 26612936
[No Abstract] [Full Text] [Related]
6. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
7. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
8. [Not Available].
Pagès F; Granier C; Kirilovsky A; Elsissy C; Tartour E
Bull Cancer; 2016 Nov; 103 Suppl 1():S151-S159. PubMed ID: 28057179
[TBL] [Abstract][Full Text] [Related]
9. Tumour immunology: Intestinal bacteria are in command.
Alderton GK
Nat Rev Immunol; 2016 Jan; 16(1):5. PubMed ID: 26655627
[No Abstract] [Full Text] [Related]
10. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive activity is attenuated by Astragalus polysaccharides through remodeling the gut microenvironment in melanoma mice.
Ding G; Gong Q; Ma J; Liu X; Wang Y; Cheng X
Cancer Sci; 2021 Oct; 112(10):4050-4063. PubMed ID: 34289209
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
14. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M; Pitt JM; Daillère R; Lepage P; Waldschmitt N; Flament C; Rusakiewicz S; Routy B; Roberti MP; Duong CP; Poirier-Colame V; Roux A; Becharef S; Formenti S; Golden E; Cording S; Eberl G; Schlitzer A; Ginhoux F; Mani S; Yamazaki T; Jacquelot N; Enot DP; Bérard M; Nigou J; Opolon P; Eggermont A; Woerther PL; Chachaty E; Chaput N; Robert C; Mateus C; Kroemer G; Raoult D; Boneca IG; Carbonnel F; Chamaillard M; Zitvogel L
Science; 2015 Nov; 350(6264):1079-84. PubMed ID: 26541610
[TBL] [Abstract][Full Text] [Related]
15. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma.
Geng H; Zhang GM; Xiao H; Yuan Y; Li D; Zhang H; Qiu H; He YF; Feng ZH
Int J Cancer; 2006 Jun; 118(11):2657-64. PubMed ID: 16425224
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Mony JT; Zhang L; Ma T; Grabosch S; Tirodkar TS; Brozick J; Tseng G; Elishaev E; Edwards RP; Huang X; Vlad AM
Cancer Immunol Immunother; 2015 Sep; 64(9):1095-108. PubMed ID: 25998800
[TBL] [Abstract][Full Text] [Related]
17. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
18. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
